Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.
Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
- Conditions
- Schizophrenic Disorder
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 535
- Registration Number
- NCT00206115
- Locations
- 🇿🇦
Research Site, Pretoria, South Africa
A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
- Conditions
- Senile Dementia, Alzheimer TypeDementiaDementia, Alzheimer TypeAlzheimer Disease
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT00208819
- Locations
- 🇺🇸
Wesley Woods Geriatric Hospital, Atlanta, Georgia, United States
Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 454
- Registration Number
- NCT00206128
- Locations
- 🇪🇸
Research Site, Villamartin, Spain
🇱🇹Research Sitte, Vilnius, Lithuania
🇩🇪Research Center, Aachen, Nordrhein-Westfalen, Germany
Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
- Conditions
- SchizophreniaSchizoaffective DisorderSubstance AbuseSubstance Dependence
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-12-13
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 20
- Registration Number
- NCT00208143
- Locations
- 🇺🇸
Creighton University Psychiatry and Research Center, Omaha, Nebraska, United States
Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder
- Conditions
- Bipolar Spectrum Disorder
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 106
- Registration Number
- NCT00182013
Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar Disorder
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-04-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00181883
Treatment of Mania Symptoms With Drug Therapy
- Conditions
- SchizophreniaBipolar Disorder
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Palo Alto Veterans Institute for Research
- Target Recruit Count
- 75
- Registration Number
- NCT00183443
- Locations
- 🇺🇸
VA Palo Alto Health Care System, Palo Alto, California, United States
Treatment of Depression With Quetiapine
- Conditions
- Major Depression With Psychotic Features
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-10
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00174603
- Locations
- 🇺🇸
Rush University Medical Center, Chicago,, Illinois, United States
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
- Conditions
- SchizophreniaSchizoaffective DisorderPsychotic DisorderAlcohol AbuseSubstance Abuse
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00156715
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸West Central Behavioral Health, Lebanon, New Hampshire, United States
🇺🇸Medical College of Georgia, Augusta, Georgia, United States
Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients
- Conditions
- Bipolar Disorder
- Interventions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17
- Registration Number
- NCT00139074
- Locations
- 🇩🇰
Research Site, Kolding, Denmark
🇩🇰Researcg Site, Svendborg, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.